An assessment of the reported impact of the COVID-19 pandemic on leprosy services using an online survey of practitioners in leprosy referral centres

Trans R Soc Trop Med Hyg. 2021 Dec 2;115(12):1456-1461. doi: 10.1093/trstmh/trab084.

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has led to governments implementing a variety of public health measures to control transmission and has affected health services. Leprosy is a communicable neglected tropical disease caused by Mycobacterium leprae and is an important health problem in low- and middle-income countries. The natural history of leprosy means that affected individuals need long-term follow-up. The measures recommended to reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can create barriers to health services. We evaluated the impact of the COVID-19 epidemic response on leprosy services and disease management.

Methods: We conducted a cross-sectional online survey with healthcare professionals in leprosy referral centres.

Results: Eighty percent of leprosy diagnostic services were reduced. All respondents reported that multidrug therapy (MDT) was available but two reported a reduced stock. Clinicians used alternative strategies such as telephone consultations to maintain contact with patients. However, patients were not able to travel to the referral centres.

Discussion: This study highlights the effects of the initial phase of the SARS-CoV-2 pandemic on leprosy services in a range of leprosy-endemic countries. Many services remained open, providing leprosy diagnosis, MDT and leprosy reaction medications. Centres developed innovative measures to counter the negative impacts of the COVID-19 pandemic.

Keywords: COVID-19; health services; leprosy; leprosy referral centres; neglected tropical diseases; pandemic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Cross-Sectional Studies
  • Drug Therapy, Combination
  • Humans
  • Leprostatic Agents
  • Leprosy* / diagnosis
  • Leprosy* / drug therapy
  • Leprosy* / epidemiology
  • Pandemics / prevention & control
  • Referral and Consultation
  • SARS-CoV-2
  • Surveys and Questionnaires

Substances

  • Leprostatic Agents